Literature DB >> 11955315

[Surgical therapeutic results of rhegmatogenous retinal detachment associated with choroidal detachment].

Jianfeng Zhu1, Xun Xu, Xi Zhang.   

Abstract

OBJECTIVE: To evaluate the effect of different factors on the prognosis of rhegmatogenous retinal detachment (RRD) associated with choroidal detachment (ChD).
METHODS: One hundred and eighty-eight eyes of 188 patients were studied retrospectively from Jan, 1996 to Aug, 1998. The clinical data, surgical management and follow-up records were analyzed.
RESULTS: The total successful rate of the surgery was 83.0%, lower than that of general RRD. In the eyes with proliferative vitreoretinopathy (PVR) A-B, the rate was 89.6%, in the eyes with C(1)-C(3) PVR, the rate was 84.1%, in D(1)-D(3), 69.0%. In eyes with severe PVR the successful rate of vitrectomy was higher than that of scleral buckling alone. Administration of steroids before surgery resulted in high successful rate, but the length of time of the steroid treatment had no effect on the successful rate. In the eyes using scleral buckling alone, the drainage or without the drainage of subretinal fluid had no effect on the successful rate.
CONCLUSIONS: RRD associated with ChD has worse prognosis than general RRD. The administration of steroids before surgery is necessary, and the timing of surgery is also important. In eyes with light PVR and ChD, scleral buckling without drainage of subretinal fluid is the first choice, but in eyes with severe PVR and ChD, vitrectomy is a better choice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11955315

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  8 in total

1.  The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment.

Authors:  Yong Wei; RongLe Zhou; Xiaobo Wang; Xiuju Chen; Hao Chen
Journal:  Eye (Lond)       Date:  2019-04-02       Impact factor: 3.775

2.  Two Patients with Atypical Choroidal Detachment.

Authors:  Joseph W Fong; Heather V Broyles; Nour Y Atassi; Ahmed B Sallam; Sami H Uwaydat
Journal:  Case Rep Ophthalmol       Date:  2021-05-03

3.  Quantitative proteomics analysis of human vitreous in rhegmatogenous retinal detachment associated with choroidal detachment by data-independent acquisition mass spectrometry.

Authors:  Shasha Luo; Huiyan Xu; Lufei Yang; Xuechun Gong; Jinyan Shen; Xuan Chen; Zhifeng Wu
Journal:  Mol Cell Biochem       Date:  2022-03-25       Impact factor: 3.396

4.  Identification of inflammatory mediators in patients with rhegmatogenous retinal detachment associated with choroidal detachment.

Authors:  Ying Dai; Zhifeng Wu; Huiming Sheng; Zhengwei Zhang; Mengxi Yu; Qing Zhang
Journal:  Mol Vis       Date:  2015-04-10       Impact factor: 2.367

5.  Ciliary body thickness changes after preoperative anti-inflammatory treatment in rhegmatogenous retinal detachment complicated by choroidal detachment.

Authors:  Yassine Alibet; Galyna Levytska; Nicolay Umanets; Natalya Pasyechnikova; Paul B Henrich
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-05-10       Impact factor: 3.117

6.  Identification of Potential Biomarkers for Rhegmatogenous Retinal Detachment Associated with Choroidal Detachment by Vitreous iTRAQ-Based Proteomic Profiling.

Authors:  Zhifeng Wu; Nannan Ding; Mengxi Yu; Ke Wang; Shasha Luo; Wenjun Zou; Ying Zhou; Biao Yan; Qin Jiang
Journal:  Int J Mol Sci       Date:  2016-12-07       Impact factor: 5.923

7.  Vitreous levels of apolipoprotein A1 and retinol binding protein 4 in human rhegmatogenous retinal detachment associated with choroidal detachment.

Authors:  Nannan Ding; Shasha Luo; Jinjin Yu; Ying Zhou; Zhifeng Wu
Journal:  Mol Vis       Date:  2018-03-26       Impact factor: 2.367

8.  Risk factors for choroidal detachment following rhegmatogenous retinal detachment in a chinese population.

Authors:  Yajie Yu; Ming An; Bin Mo; Zhen Yang; Wu Liu
Journal:  BMC Ophthalmol       Date:  2016-08-09       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.